A pooled analysis of clinical trials testing inclisiran (Novartis) that confirms the agent’s potent effects on LDL cholesterol has now been published. Yet the small interfering RNA (siRNA) molecule, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In adults with atherosclerotic CVD or a risk ...
WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...
ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...
Madrid, Spain – 30 August 2025: More patients with hypercholesterolaemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran ...
The US Food and Drug Administration (FDA) issued a complete response letter regarding Novartis' new drug application (NDA) for inclisiran, a novel treatment for elevated low-density lipoprotein ...
Please provide your email address to receive an email when new articles are posted on . “Patients with hyperlipidemia and established cerebrovascular disease are at an increased risk of future strokes ...
Novartis bought cholesterol drug inclisiran on the brink of a new drug filing as the centerpiece of its $9.7 billion acquisition of The Medicines Company. But, in the wake of an FDA rebuff amid the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback